Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Effect of Lipedema on Knee Osteoarthritis

3. maj 2026 opdateret af: Kadir Songur, Izmir Democracy University

The Effect of Lipedema on Knee Osteoarthritis: A Cross-Sectional Analysis of Clinical Symptoms and Ultrasonographic Findings

This study will be one of the few to examine the effect of lipedema on knee osteoarthritis in a comparative manner with a control group within the same osteoarthritis context. Although the relationship between obesity and osteoarthritis has been extensively studied in the literature, the effect of specific adipose tissue pathologies, such as lipedema, on osteoarthritis has not been sufficiently investigated. This study aims to demonstrate the independent effect of lipedema on osteoarthritis, evaluate clinical and ultrasonographic parameters together, and contribute to early diagnosis and targeted rehabilitation strategies.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

76

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Kadir Songür, Assoc. Prof.
  • Telefonnummer: +905054529231
  • E-mail: kadir.93@gmail.com

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

This study will include patients aged 30 and older who presented to the Physical Medicine and Rehabilitation Outpatient Clinic at Buca Seyfi Demirsoy Training and Research Hospital, Izmir Democracy University, between July 15, 2026, and July 15, 2027, and who were diagnosed with knee osteoarthritis based on clinical and radiological evaluations. Previously obtained knee X-rays will be retrospectively reviewed, and patients with osteoarthritis findings on X-rays according to the Kellgren-Lawrence grading system will be included in the study. The diagnosis of lipedema will be made by an experienced physical therapy and rehabilitation specialist based on a combined evaluation of clinical and ultrasonographic findings. The clinical diagnosis will be based on the Wold criteria: bilateral and symmetrical fat distribution in the lower extremities, foot sparing, tenderness and pain on palpation, a history of easy bruising, and fat accumulation resistant to diet and exercise.

Beskrivelse

Inclusion Criteria:

All participants (Group 1 + Group 2)

  • Women aged 30-65
  • With a clinical and radiological diagnosis of knee osteoarthritis
  • Who agreed to participate in the study

Group 1 (knee osteoarthritis with lipedema):

  • Patients who meet the Wold criteria for a clinical diagnosis of lipedema
  • An increase in subcutaneous fat thickness confirmed by ultrasound

Group 2 (knee osteoarthritis without lipedema):

  • No diagnosis of lipedema
  • Exclusion of lymphedema and venous diseases

Exclusion Criteria:

  • Inflammatory arthritis
  • History of knee surgery
  • Intra-articular injection within the past 6 months
  • Acute trauma
  • Systemic connective tissue disease
  • Severe venous insufficiency or lymphedema
  • History of malignancy
  • Use of gabapentinoids/SNRIs/SSRIs due to fibromyalgia or psychiatric illness
  • Severe cognitive impairment or communication problems that would prevent participation in the study
  • Pregnancy
  • Participants who were informed about the study and refused to participate

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Group 1
Knee osteoarthritis with lipedema
Group 2
Knee osteoarthritis without lipedema

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ultrasonography-based measurements of femoral cartilage thickness
Tidsramme: Day 1
During femoral cartilage thickness measurements, participants will be positioned in the supine position, and the knee will be brought to maximum flexion for evaluation through the suprapatellar window. The probe will be positioned in the transverse plane, and measurements will be taken at the level of the medial and lateral femoral condyles and the intercondylar groove. For standardization, each measurement will be repeated three times, and the average will be recorded. Cartilage thickness will be defined as the distance between the hypoechoic cartilage layer and the subchondral bone surface. Lower values indicate that osteoarthritis has caused more structural damage.
Day 1

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Western Ontario og McMaster Universities (WOMAC) score
Tidsramme: Dag 1
WOMAC Osteoarthritis Index-spørgeskemaet, som består af 5 spørgsmål ved brug af en Likert-skala, er tilgængeligt i den vedlagte case report form for at vurdere smerter, stivhed og funktioner i dagligdagen.
WOMAC Osteoarthritis Index indeholder 24 spørgsmål, der dækker tre subskalaer: smerter (5 spørgsmål), stivhed (2 spørgsmål) og funktion (17 spørgsmål).
Scoringssystemet består af WOMAC smerte-score, WOMAC stivhed-score, WOMAC funktions-score og WOMAC total-score.
Der er udført et tyrkisk validitets- og pålidelighedsstudie.
Dag 1
Visuel analog skala
Tidsramme: Dag 1
Visual analog skala måler smerte, som den opleves subjektivt. Den bruger en 0-10 cm skala, det mest almindeligt anvendte værktøj til kvantitativ bestemmelse af smerteintensitet, hvor den ene ende repræsenterer ingen smerte og den anden ende repræsenterer den mest intense smerte muligt. '0' angiver ingen smerte, mens '10' angiver den mest intense smerte. Den enkelte bliver bedt om at vælge den numeriske værdi, der bedst repræsenterer deres tilstand. Denne markerede værdi bruges som numerisk data til at bestemme niveauet for smerteopfattelse. En højere score indikerer et højere smerte niveau.
Dag 1
Måling af bevægelighed i led
Tidsramme: Dag 1
Knæfleksion og -ekstension måles bilateral ved anvendelse af universel goniometri for at vurdere patienters ledbevægelighed, og vinklerne registreres.
Dag 1
Kellgren-Lawrence-klassifikation
Tidsramme: Dag 1
Kellgren og Lawrence-systemet er en bredt anvendt metode, der klassificerer sværhedsgraden af knæartrose i fem grader.
Dag 1
Assessment of osteophytes via ultrasonography
Tidsramme: Day 1
During osteophyte assessment, participants will be positioned in the supine position with the knee flexed approximately 30 degrees; the probe will be placed along the medial and lateral joint lines in the longitudinal and transverse planes to examine bony projections. Osteophytes will be scored according to the Outcome Measures in Rheumatology knee osteoarthritis scale criteria as small (<2 mm - Grade 1), moderate (2-4 mm - Grade 2), and large (>4 mm - Grade 3).
Day 1
Assessment of synovial hypertrophy via ultrasonography
Tidsramme: Day 1
In the ultrasound assessment of synovial hypertrophy, the thickness of hypoechoic tissue in the suprapatellar region that does not shift upon probe compression will be measured, and values exceeding 2 mm will be recorded as synovial hypertrophy.
Day 1
Assessment of synovial effusion via ultrasonography
Tidsramme: Day 1
Ultrasonographic assessment of joint effusion will be performed at the suprapatellar recess level; participants will be positioned in the supine position with the knee in near-extension or slight flexion. During the longitudinal plane examination, anechoic fluid collections will be measured, and values of 4 mm or greater will be considered pathological synovial effusions.
Day 1
Assessment of meniscal protrusions via ultrasonography
Tidsramme: Day 1
During the ultrasound assessment of meniscus protrusion, the knee will be positioned with approximately 30 degrees of flexion, and the extent to which the meniscus tissue extends beyond the tibial margin will be evaluated in measurements taken in the longitudinal plane along the medial joint line; protrusions exceeding 3 mm will be considered pathological meniscus protrusions.
Day 1
Ultrasonography-based measurements of quadriceps muscle thickness
Tidsramme: Day 1
For ultrasonographic measurements of quadriceps muscle thickness, participants will be positioned in the supine position with the knee extended and the muscles fully relaxed; measurements taken in the transverse plane at the midpoint between the anterior superior iliac spine and the superior pole of the patella will assess the thicknesses of the rectus femoris and vastus intermedius muscles together.
Day 1
Ultrasonography-based measurements of quadriceps tendon thickness
Tidsramme: Day 1
Ultrasonographic measurements of the quadriceps tendon will be taken in the longitudinal plane immediately proximal to the superior pole of the patella while the knee is flexed to approximately 30 degrees, and the average of the measurements taken 5, 10, and 15 mm proximal to this point will be recorded
Day 1
Ultrasonography-based measurements of patellar tendon thickness
Tidsramme: Day 1
Ultrasonographic assessment of the patellar tendon is performed with the knee flexed to 30 degrees, in the longitudinal plane from the apex of the patella distally, and the anteroposterior thickness is measured approximately 5 mm distal to the apex.
Day 1

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ultrasonography-based measurements of pre-tibial and thigh subcutaneous thickness
Tidsramme: Day 1
The diagnosis of lipedema will be supported by ultrasonographic measurements of subcutaneous fat thickness in the thigh and pretibial regions. With the patient in the supine position and the lower extremities relaxed and in a neutral position, the probe is placed in the transverse plane (anterior surface of the tibia), at the midpoint between the tibial tuberosity and the medial malleolus, and on the thigh, at the midpoint along the midline between the iliac crest and the lower edge of the patella, and the total thickness of the skin and subcutaneous tissue will be measured in millimeters by applying minimal pressure. Each measurement will be taken three times, and the average will be calculated. In the literature, diagnostic threshold values have been established as a thickness measurement of >11.7 mm in the pre-tibial region and >17.9 mm in the thigh.
Day 1

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Izmir Democracy University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. juli 2026

Primær færdiggørelse (Anslået)

15. juli 2027

Studieafslutning (Anslået)

15. august 2027

Datoer for studieregistrering

Først indsendt

3. maj 2026

Først indsendt, der opfyldte QC-kriterier

3. maj 2026

Først opslået (Faktiske)

8. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 2026/26

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared because the data contain

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Knæ slidgigt

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Luxembourg

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner